Cerus (NASDAQ:CERS – Free Report) had its price objective raised by Cantor Fitzgerald from $3.00 to $4.00 in a research report sent to investors on Friday morning, Benzinga reports. They currently have an overweight rating on the biotechnology company’s stock. A number of other analysts have also commented on CERS. Stephens reiterated an equal weight […]
Cerus (NASDAQ:CERS – Get Free Report) and Co-Diagnostics (NASDAQ:CODX – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, valuation, earnings, risk, institutional ownership and profitability. Risk and Volatility Cerus has a beta of 1.31, […]
Cerus Co. (NASDAQ:CERS – Get Free Report) saw a significant growth in short interest in January. As of January 31st, there was short interest totalling 4,480,000 shares, a growth of 5.9% from the January 15th total of 4,230,000 shares. Based on an average trading volume of 1,420,000 shares, the short-interest ratio is presently 3.2 days. […]
Cerus Co. (NASDAQ:CERS – Get Free Report) Director Eric Bjerkholt acquired 10,000 shares of Cerus stock in a transaction dated Wednesday, December 13th. The stock was acquired at an average cost of $1.62 per share, with a total value of $16,200.00. Following the completion of the transaction, the director now directly owns 142,133 shares of […]
Cerus (NASDAQ:CERS – Get Free Report) and Tenon Medical (NASDAQ:TNON – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, earnings, institutional ownership, dividends, analyst recommendations, valuation and profitability. Volatility and Risk Cerus has a beta of […]